NCT01156259CompletedPhase 3
30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
30 Gy Versus 40 Gy Consolidative Radiotherapy for Early-stage Diffuse Large B-cell Lymphoma After Complete Response to Chemotherapy: a Multicentre, Randomised, Phase 3, Non-inferiority Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to determine whether 30Gy radiotherapy is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 432 (actual)
- First submitted
- 29 Jun 2010
- Start date
- 14 Jul 2010
- Primary completion date
- Jul 2025
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- NCT number
- NCT01156259
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 432
- From 14 Jul 2010 to the primary completion date, Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent condition precluding protocol treatment.
- Chemotherapy or radiotherapy before trial enrolment.
Other illness
- HIV seropositivity.
- Previous malignancy other than cervical carcinoma in situ.
- Hepatic or cardiac failure.
Other
- Primary lymphoma of the central nervous system, skin, or testis.
- Transformation from another indolent lymphoma.
- Pregnancy or breastfeeding.
Who the study is looking for
- Written informed consent obtained before any trial-specific procedure.
- Age 15 years or older.
- Newly diagnosed, histologically confirmed DLBCL or primary mediastinal B-cell lymphoma (PMBL).
- Ann Arbor stage I or II disease.
- Complete response after chemotherapy, defined as the absence of clinical or imaging evidence of active disease, or a Deauville score of 1-3 on PET/CT.
- An interval of less than 90 days between completion of chemotherapy and radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Able to receive conformal radiotherapy and to complete the required follow-up.
Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.